Retatrutide is an investigational GLP-1, GIP, and glucagon triple receptor agonist not yet licensed by the MHRA or EMA in the UK
Appropriate monitoring will be necessary for GLP-1R agonists use in the treatment of patients with lipodystrophy
Conversely, palmitate alone and palmitate in combination with high concentrations of glucose did not induce ER-stress in EndoC-H1 cells (63)
Nothing contained on this page is intended to create a doctor-patient relationship, replace or be a substitute for a registered medical practitioner's medical treatment/advice or consultation
I have had MS for 20 years and would never use GLP-1 drugs - its too risky when there are healthier, more sustainable methods
Beharier O, Tyurin VA, Goff JP, Guerrero-Santoro J, Kajiwara K, Chu T, et al